Scrip
US FDA approves AstraZeneca's Crestor for broader patient population
09 February 2010
Asher Mullard
Please Login to read the full article.
09 February 2010
Asher Mullard
The US FDA has expanded the approval of AstraZeneca's Crestor (rosuvastatin) such that it can now be used to prevent heart disease in individuals with normal low-density lipoprotein (LDL) levels and no clinically relevant heart disease, so long as they have other risk factors.
As...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US FDA panel to mull JUPITER-based prevention indication for Crestor
- Abbott's Niaspan beats Merck & Co's Zetia in halted trial
- US FDA advisors back AstraZeneca's Crestor for CV disease prevention
- ACCORD LIPID: Fenofibrates fail to improve cardiovascular outcomes type 2 diabetics
ANALYSIS
Other Informa Analysis
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
